Adoptive cell-transfer therapy (ACT) has been reported to suppress growing tumors and to overcome tumor escape in animal models. As a candidate ACT effector, c9d2T cells can be activated and expanded in vitro and in vivo and display strong antitumor activity against colorectal, lung, prostate, ovarian and renal cell carcinomas. However, it is difficult to obtain a large enough number of cdT cells to meet the need for immunotherapy that can overcome the cancer patients' immune suppressive tumor microenvironment. In previous studies, our lab confirmed that c9d2T cells recognized tumor cells via the CDR3d region of the cd-T-cell receptor (TCR). We constructed full-length human peripheral blood mononuclear cell (PBMC)-derived c9 and d2 chains in which the CDR3 region was replaced by an ovarian epithelial carcinoma (OEC)-derived CDR3. We transferred the CDR3d-grafted c9d2TCR into peripheral blood lymphocytes (PBLs) to develop genetically modified c9d2T cells. In vitro studies have shown that these CDR3d-grafted c9d2T cells can produce cytokines after stimulation with tumor cell extracts and exhibit cytotoxicity towards tumor cells, including human OEC and cervical adenocarcinoma. CDR3d-grafted c9d2T cells adoptively transferred into nude mice bearing a human OEC cell line demonstrated significant antitumor effects. These results indicate that CDR3d-grafted c9d2T cells might be candidates for clinical tumor immunotherapy.
INTRODUCTION
Adoptive cell-transfer therapy (ACT) is a promising immunotherapy strategy that has been reported to suppress growing tumors and to overcome tumor escape in both animal models and human patients [1] [2] [3] [4] However, ACT has had limited clinical success in cancer treatment due to the requirement of preexisting tumor-reactive cells 5 Genetic modification of autologous lymphocytes with antigen-specific T-cell receptors (TCRs) is a promising potential tool for solving this problem, as these cells have shown antitumor effects both in vitro and in vivo. [6] [7] [8] [9] Moreover, clinical studies have shown that transfer of genetically modified T cells resulted in objective regression of metastatic melanoma in a certain percentage of patients 10 The challenge of applying genetically modified T cells in cancer immunotherapy is the autoreactivity of those cells, as their TCRs are hybrids consisting of one exogenous and one endogenous chain. 11 A novel strategy for generating non-autoreactive T cells with antitumor specificity could greatly improve upon current cancer immunotherapies.
cdT cells, a T-cell subset, directly recognize tumor antigens through the cdTCR, bypassing traditional antigen-presenting cell-mediated antigen recognition 12 cdT cells have a broad TCR repertoire, recognizing an array of antigens including nonpeptide phosphoantigens, mitochondrial ATPase and human mutS homolog 2, [13] [14] [15] some of which cannot be recognized by abT cells. c9d2T cells belong to the major subset of cdT cells in peripheral blood, and are regarded as a potential candidate for tumor immunotherapy because this subset has been shown to display strong antitumor activity against different type of cancer cells. [16] [17] [18] [19] [20] However, the low frequency of c9d2T cells in peripheral blood greatly limits their potential clinical applications. c9d2T cells account for only 2-5% of the total peripheral blood T-cell repertoire. Expansion of these cells for ACT requires laborious and time-consuming cell culture procedures. Moreover, in the patients with median-stage or late-stage malignant tumors or who are being treated with chemotherapy, neither the quantity nor immunological activity of their seed c9d2T cells can meet the treatment demands. As the antitumor effect of c9d2T cells mainly depends on the cdTCR, which cannot exchange chains with the abTCR, 21, 22 we hypothesized that large numbers of cytolytic cdT cells could be generated through forced expression of cdTCRs on lymphocytes.
Antigen recognition by cdTCRs depends on the sequence of its peptide, especially that of complementarity determining region 3 (CDR3). Compared with the c-chain, the sequence of the d-chain CDR3 region is both longer and more variable. 23 This suggests that the CDR3d may play a vital role in antigen recognition by the cdTCR. Adams et al. analyzed the crystal structures of the G8 cdTCR with a T22 molecule as its antigen and found that the G8 CDR3d formed a loop which directly contacted T22 24 Previously, our lab confirmed that the c9d2TCR recognized tumor antigens via the CDR3d region. We synthesized OT3, a CDR3d peptide derived from tumor-infiltrating lymphocytes (TILs) in ovarian epithelial carcinoma (OEC). Our data demonstrated specific interactions between OT3 and tumor cells, tumor tissues and tumor cell extracts. 25 The OT3 sequence is sufficient for tumor recognition by the TCR, as a CDR3d-grafted antibody, in which the heavy chain CDR3 region was replaced by the OT3 sequence, showed specific binding to tumor cell lines. 19 We have generated genetically modified T cells by forcing the expression of CDR3d-grafted c9d2TCR on peripheral blood lymphocytes (PBLs). PBLs transfected with the c9d2 (OT3) vector successfully express the c9d2 (OT3) TCR on the cell surface. CDR3d-grafted c9d2T cells showed cytotoxic activity against tumor cells, including human OEC and cervical adeno-carcinoma, and marked cytokine production when stimulated with tumor extracts. Adoptive transfer of CDR3d-grafted c9d2T cells into nude mice bearing a human OEC cell line resulted in significant therapeutic effects. These results implicate CDR3d-grafted c9d2T cells as a promising tumor-repression tool with applications in clinical cancer therapy.
MATERIALS AND METHODS

Cell culture
Human tumor cell lines, including HeLa (a human uterine cervix carcinoma), Daudi (a Human Burkitt's lymphoma) and Raji (a Human Burkitt's lymphoma cell line), were obtained from the Cell Culture Center, Institute of Basic Medicine, Chinese Academy of Medical Sciences, Beijing, China. The human OEC lines SKOV3 and HO8910 were provided by Dr Keng Shen (Department of Gynecology, Peking Union Medical College Hospital, Beijing, China). The RetroPack PT67 cell line was purchased from Clontech Laboratories, Inc, Clontech Laboratories, Mountain View, CA, USA. SKOV3 cells were cultured in McCoy5A medium (Sigma, St Louis, MO, USA) with 10% fetal bovine serum (HyClone). The HO8910, Daudi and Raji cell lines were maintained in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum. HeLa and RetroPack PT67 cells were propagated in Dulbecco's modified Eagle's medium (Sigma) with 10% fetal bovine serum. Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors granting informed consent by density gradient centrifugation on Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA). PBMCs were stimulated for 3 days with immobilized anti-CD3 antibody (UCHT1; BD Pharmingen, San Diego, CA, USA) and IL-2 (200 IU/ml).
Plasmid construction and viral production
The full-length sequence of the c9 and d2 chains with a tumor antigenspecific CDR3 region derived from OEC TILs has been described previously 26 Briefly, the full-length c9 and d2 sequence was amplified from PBMC cDNA from a healthy donor by PCR using primers directed at the 5'-untranslated region (UTR) and 3'-UTR of each chain. The first half of the full-length c9 or d2 sequence was amplified using a forward primer targeting the 5'-UTR and a reverse complement primer directed at the CDR3. The second half of the full-length c9 or d2 sequence was amplified using a forward primer targeting the CDR3 region and a reverse primer targeting the 3'-UTR. The overlapped PCR products were used as templates for the generation of a d2 sequence containing the tumor antigen-specific CDR3 sequence. The fulllength c9 sequence was inserted into a BglII and XhoI-treated pMSCVhyg vector and was named pMSCVhyg-c9. The PCR product from the full-length d2 chain containing the tumor antigen-specific CDR3 region was subcloned into the XhoI and BglII-site of the pMSCVneo vector and was named pMSCVneo-d2 (OT3). All plasmids were sequenced using ABI 3770 automatic sequencer (Applied Biosystems, Foster City, CA, USA), which confirmed the sequences had been cloned correctly. The pMSCVhyg-c9, pMSCVneo-d2 (OT3), pMSCV-hyg and pMSCV-neo vectors were transfected into a RetroPack PT67 cell line by using the Lipofectamine 2000 kit (Invitrogen, Carlsbad, CA, USA). Hygromycin and neomycin were added to the transfected packaging cells for 2 weeks. The retroviral supernatant was concentrated and stored at 280 uC.
Peripheral blood lymphocytes transfected with retrovirus PBLs isolated from healthy donors were stimulated for 3 days and transfected using a modified version of the method described by Bunnell et al 27 Briefly, 1310 6 cells/ml in media containing retrovirus and 200 IU/ml IL-2 were transferred into non-tissue culture 24-well plates precoated with Retronectin (recombinant human fibronectin fragment CH-296, 20 mg/cm 2 ; Takahara, Otsu, Japan). Plates were centrifuged at 300g for 90 min at 32 uC and incubated overnight at 37 uC in a humidified 5% CO 2 incubator. This transfection procedure was then repeated two more times. On day 8, PBLs were selected in geneticin (0.5 mg/ ml) and hygromycin B (0.1 mg/ ml) for 3 days. The live cells were adjusted to 1310 6 cells/ml and maintained in culture medium supplemented with 200 IU/ml IL-2 until day 14.
Reverse transcription (RT)-PCR analysis of cdTCR expression
The mock-transfected and TCR-transfected cells were harvested after retroviral transfection. Total RNA was prepared using TRIzol regent (Invitrogen) according to the manufacturer's protocol. The RNA quality was evaluated with 1% agarose gel electrophoresis. Single-strand cDNA was synthesized using oligo-dT (Promega, Madison, WI, USA) and moloney murine leukemia virus reverse transcriptase (Promega). Single-strand cDNA was used as a template for PCR amplification of the full-length c9 chain, the full-length d2 chain, the c9 chain CDR3 region, the d2 chain CDR3 region and b-actin used for normalization. The following primer sequences were used for amplification: c9-5: GAAGATCTGCCACCATGCTGTCACTGCTCCACACAT; c9-3: CC-GCTCGAGTGATTTCTCTCCATTGCAGCAG; d2-5: CCGCTCGAG-GCCACCATGCAGAGGATCTCCTCCCTCATCC; d2-3: GAAGATC-TCTTACAAGAAAAATAACTTGGCAGTC; CDR3c9-5: AATGTAGA-GAAACAGGAC; CDR3c9-3: ATCTGTAATGATAAGCTTT; CDR3d2-5: GCCATTGAGTTGGTGCCTGAACAC; CDR3d2-3: AAACGGATG-GTTTGGTATGAGGC; b-actin-5: GCTCGTCGTCGACAACGGCT; bactin-3: CAAACATGATCTGGGTCATCTTCTC. PCR products were resolved using a 1% agarose gel.
Western blot analysis of cdTCR expression
The transfected cells were harvested and lysed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer. Total cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrically transferred onto a nitrocellulose membrane. After blocking with 5% nonfat milk, the blot membrane was incubated with an anti-c9 antibody (Immunotech, Marseille, France) as the primary antibody. After incubation with a horseradish peroxidase-conjugated secondary antibody, enhanced chemiluminescence was performed using the SuperSignal West Pico Trial Kit (Pierce Biotechnology Inc., Rockford, IL, USA). The glyceraldehyde 3-phosphate dehydrogenase antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Flow cytometric analysis
Cells (1310 6 ) were harvested, washed and suspended in 50 ml phosphate-buffered saline (PBS) containing 1% bovine serum albumin CDR3d-grafted c9d2T mediate antitumor reactivity H Zhao et al 148 FITC-and phycoerythrin-conjugated antibodies were added to each reaction. After incubation for 30 min at 4 uC, cells were washed twice, resuspended in 500 ml PBS containing 1% formaldehyde and analyzed on a FACSort flow cytometer (Becton Dickinson, Mountain View, CA, USA). FITC-conjugated anti-TCRcd (IMMU510), phycoerythrin-conjugated anti-TCRab (BMA031) and the respective isotype control monoclonal antibodies (mAbs) were purchased from Immunotech.
Cytokine release assay
The transfected cells were tested for antitumor cell reactivity using a cytokine release assay. Twenty-four-well plates were treated with 40 mg/ml SKOV3, HO8910, HeLa, Daudi and Raji cell extracts for 2 h at 37 uC. After three washes, 1310 6 cells transfected cells were plated in complete medium containing 200 IU/ml IL-2. After 24 or 72 h of coculture, the supernatants were harvested. Interferon (IFN)-c and tumor necrosis factor (TNF)-a secretion were measured using enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. For the blocking assay, effector cells were incubated with 10 mg/ml anti-TCRcd mAbs (B1.1; eBioscience, San Diego, CA, USA) or isotype control for 2 h at 37 uC and then cocultured with SKOV3, HO8910 and HeLa extracts. Supernatant IFN-c production was measured using ELISA.
Cytotoxicity and blocking assay
The cytotoxicity of the transfected cells was assessed using a colori- ) was added to each well (10 ml/well) and incubated at 37 uC for an additional 4 h. The reaction was stopped by adding 100 ml dimethyl sulfoxide to dissolve the tetrazolium crystals. The plate was read at 570nm with 630nm correction using a Multiskan Microplate Reader (Thermo Labsystems, Helsinki, Finland) and cytotoxicity was calculated using the following formula: T OD -[(E1T ) OD -E OD ]/T OD 3100%, where T OD 5optical density (OD) value of target cells, E OD 5OD value of effector cells and (E1T) OD 5OD value of effector cells cultured with target cells.
For the blocking assay, effector cells were incubated with 10 mg/ml anti-TCRcd mAbs (B1.1; eBioscience) or isotype control for 2 h at 37 uC and then cocultured with the target cells. For the anti-Fas antibody blocking assay, target cells were incubated with a saturating concentration of anti-Fas mAbs (ZB4; Immunotech) for 2 h at 37 uC and then cocultured with the effector cells. In other experiments, the effector cells were treated with a saturating concentration of concanamycin A (CMA; Sigma-Aldrich, Munich, Germany) and brefeldin A (BFA; Sigma-Aldrich) for 2 h, mixed with target cells at an effector/ target (E/T) ratio of 10 : 1 and then subjected to cytotoxicity assays.
Mice
Athymic BALB/c nu/nu mice (female, 4-6 weeks) were purchased from the Laboratory Animal Center of the Chinese National Institute for the Control of Pharmaceutical and Biological Products. Mice were maintained in micro-isolator cages in a specific pathogenfree facility at the Animal Center, Institute of Basic Medical Sciences, CAMS. The care and use of animals were approved by the Animal Use Committees of the CAMS Institute.
Animal tumor model
To test the antitumor effects of the CDR3d-grafted c9d2T cells in vivo, SKOV3 cells (1310 6 ) were injected subcutaneously in the back right flank of BALB/c nu/nu mice. When the majority of tumors grew to a size of approximately 100 mm 3 , mice bearing tumors were randomly divided into three groups and injected intratumorally with CDR3d-grafted c9d2T cells (1310 6 , n56), mock-transfected cells (1310 6 , n56) or PBS (1310 6 , n56). Human IL-2 was administrated intraperitoneally at a dose of 5000 IU for all mice in the CDR3d-grafted c9d2T cells and mock-transfected cell-treated groups. The treatment was repeated every 3 days for a total of four times. The general condition of the nude mice and tumor progression were observed every 2 days. Tumor volumes were estimated using the formula 3.143[largest diameter3(perpendicular diameter) 2 ]/6. Mouse survival was also observed.
Statistical analysis
Data were presented as means6s.d. Repeated measures analysis of variance and independent samples t-tests were used to analyze all data as indicated in the results and in the figure legends. The log rank test was used in Kaplan-Meier survival analysis. When P was ,0.05, the difference was considered statistically significant.
RESULTS
Construction of CDR3d-grafted c9d2TCR-transfected lymphocytes
The c9 and d2 chains were PCR-amplified from PBMC cDNA from healthy donors. The CDR3 region of the d2 chain was replaced with the tumor antigen-specific CDR3 sequence of the TILs from the OEC (Figure 1a) . The full-length c9 and d2 sequences with the tumor antigen-specific CDR3 sequences were cloned into retroviral vectors. Stimulated PBLs from healthy donors were transfected with a retrovirus containing the c9 and d2 chain. After transfection, the cdTCR expression on the expanded cells was assessed using RT-PCR, western blotting and flow cytometric analysis. The RT-PCR assay showed that the c9 and d2 chain cDNA containing the tumor antigen-specific CDR3 sequences were successfully expressed in PBLs (Figure 1b) . The expression of the c9 and d2 chains was confirmed by western blot (Figure 1c ). After transfection with the c9 and d2 chains about 70% of PBLs successfully expressed the cdTCR on the cell surface, while only 3% of PBLs transfected with mock vector did so (Figure 1d ).
Recognition and cytotoxicity of CDR3d-grafted c9d2TCR-transfected lymphocytes (CDR3d-grafted c9d2T cells) After transfection with c9 and d2 chain, the CDR3d-grafted c9d2T cells were incubated with tumor cell extracts to investigate cytokine production. After 72 h, IFN-c concentration in the supernatant was evaluated. As shown in Figure 2a , CDR3d-grafted c9d2T cells secreted more IFN-c than mock-transfected cells after stimulation with Daudi cell extract. CDR3d-grafted c9d2T cells and mock-transfected T cells had no significant differences in IFN-c secretion after stimulation with Raji cell extract. CDR3d-grafted c9d2T cells produced much more IFN-c than mock-transfected cells after stimulation with HeLa, SKOV3 and HO8910 cell extracts (P,0.01). TNF-a production by CDR3d-grafted c9d2T cells after stimulation with various tumor cell extracts was also measured. CDR3d-grafted c9d2T cells produced more TNF-a than mock vector-transfected T cells after stimulation with HeLa, SKOV3 and HO8910 cell extracts. An MTT assay was used to test the transfected T-cell cytotoxicity. The results showed that CDR3d-grafted c9d2T cells effectively killed HeLa and HO8910 cells and were particularly effective at killing SKOV3 cells (Figure 2c) . The
CDR3d-grafted c9d2T cell cytotoxicity was as twofold higher than mock-transfected cells at an E/T ratio of 20 : 1 (P,0.01). The above results suggest that the observed antitumor effects of CDR3d-grafted c9d2T cells is cdTCR-dependant. As shown in Figure 3 , CDR3d-grafted c9d2T cell IFN-c production after stimulation with tumor cell extracts was inhibited by an anti-TCR mAb (P,0.05) (Figure 3a) , and the transfected T-cell killing of tumor cells was significantly blocked by an anti-TCR mAb (Figure 3b-d) .
Cytotoxic mechanism of CDR3d-grafted c9d2T cells To further investigate the CDR3d-grafted c9d2T cell antitumor cytotoxic mechanisms, tumor cells were treated with an anti-Fas mAb at several different concentrations before incubation with effector cells. The effector cell killing ability decreased as anti-Fas mAb concentration increased. As shown in Figure 4a , the killing inhibition rate of HO8910, SKOV3 and HeLa cell lines with 5000 ng/ml anti-Fas mAb added to culture was 29.41%, 18.13% and 22.91%, respectively. Similar results were measured after treatment with BFA, a protein transport inhibitor that can block Fas ligand surface expression on effector cells. When CDR3d-grafted c9d2T cells were treated with BFA, the antitumor killing ability decreased in a dose-dependant manner and peaked with the addition of 25 mM BFA to culture (Figure 4b ). This suggested that the CDR3d-grafted c9d2T cells cytotoxic mechanism was Fas-FasL-related, but did not entirely depend on Fas-FasL pathway. Therefore, we theorized that the perforin-granzyme B pathway might be involved. To test if this pathway played a role, CDR3d-grafted c9d2T cells were treated with CMA, an inhibitor of the perforin-granzyme B pathway, at different concentrations before incubation with tumor cells. This treatment inhibited killing in a dose-dependant manner, reaching the peak level of inhibition at a concentration of 100 nM. Killing of HO8910, SKOV3 and HeLa cell lines was inhibited by 33.93%, 56.71% and 46.52%, respectively (Figure 4c) . When CMA and BFA treatment were combined with a concentration of 100 nM and 25 mM, respectively, CDR3d-grafted c9d2T-cell cytotoxicity was inhibited by over 60% against all three tumor cell lines (Figure 4d) . These results suggested that both the Fas-FasL and perforin-granzyme B pathways play a role in CDR3d-grafted c9d2T-cell killing of tumor cells, and that the perforin-granzyme B pathway could play a major role.
In vivo antitumor activity of CDR3d-grafted c9d2T cells We further investigated the antitumor efficacy of the CDR3d-grafted c9d2T cells in vivo BALB/c nude mice were subcutaneously inoculated with SKOV3 cells. When the tumor mass grew to approximately The transfected effector cells were incubated with HeLa, SKOV3 and HO8910 target cells at different effector-to-target ratios for 8 h MTT solution (5 mg/ml) was added to each well (10 ml/well) and cells were incubated at 37 uC for an additional 4 h. The reaction was stopped by the addition of 100 ml DMSO to dissolve the tetrazolium crystals. The plate was examined at 570nm with 630nm correction in a Multiskan Microplate Reader. Asterisks indicate significant differences compared to the mock control: *P,0.05, **P,0.01. All data are representative of three independent experiments. DMSO, dimethylsulfoxide; IFN, interferon; MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide. Figure 3 The antitumor effects of CDR3d-grafted c9d2T cells were blocked by an anti-TCRcd mAb. (a) CDR3d-grafted cdT cells were incubated with an anti-TCRcd mAb, a mouse IgG1 isotype control or no mAb for 2 h and then stimulated with tumor cell extracts for 72 h. IFN-c secretion in the supernatants was detected by ELISA. (b-d)The CDR3d-grafted c9d2T cells were incubated with an anti-TCRcd mAb, mouse IgG1 isotype control or no treatment for 2 h and then cocultured with tumor target cells at different E/T ratios. The MTT assay was used to evaluate cytotoxicity. Asterisks indicated significant differences compared to the mock control, *P,0.05, **P,0.01. The results are representative of three independent experiments. E/T, effector/target; IFN, interferon; mAb, monoclonal antibody; MTT, 3-(4,5-dimethylHSthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TCR, T-cell receptor.
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100 mm 3 , CDR3d-grafted c9d2T cells, mock-transfected cells, or PBS were injected intratumorally every 3 days for a total of four injections. Mice treated with CDR3d-grafted c9d2T cells showed slowed tumor growth compared to mice treated with mock-transfected cells or PBS (P,0.05, Figure 5a) , whereas mock-transfected T cell-treated mice and PBS-treated mice displayed similar tumor progression (P.0.05). Intratumoral injections of CDR3d-grafted c9d2T cells not only delayed the early stage tumor development but also prolonged the survival of the treated mice. As shown in Figure 5b , the median survival time of mice in the PBS treated group was 37 days and the maximum survival time was 49 days. The median survival time of mice treated with mock-transfected cells was 40 days. In contrast, the median survival time of mice treatment with CDR3d-grafted c9d2T cells was 47 days, significantly longer than the PBS-treated and mock-transfected T cell-treated groups (P,0.05).
DISCUSSION
cdT cells have unique characteristics that are not seen in abT cells. cdT cells can directly recognize antigens without MHC restriction, 12 have a wide antigen recognition spectrum, which includes protein antigens and phosphoantigens 13 and can directly kill several tumor types including colorectal, lung, prostate, ovarian and renal cell carcinomas. 16, 18, 25, 28, 29 Because of these features, cdT cells are an interesting candidate effector for antitumor immune therapy. There are two commonly available strategies for using cdT cells in cancer therapy. One is to stimulate cdT cells in vivo and the other is to expand cdT cells in vitro. 30 Both strategies require a large number of cdT cells with high avidity and potent antitumor activity. However, the quantity and specificity of resulting cdT cells correlate with the original repertoire of cdT cells isolated from patients. Because of cancer patients' immune suppressive tumor microenvironment, seed cdT cells are difficult to isolate and expand in vitro. Because cdT cells show natural antitumor activity, we hypothesized that their tumor reactivity could be used to construct genetically modified cdT cells, overcoming the previously mentioned problems. Moreover, genetically modified cdT cells may avoid the disadvantage of genetically modified abT cells in which hybridization can result in TCRs with potentially autoreactive specificities.
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To generate genetically modified cdT cells, we needed to find a cdTCR that could both recognize tumor antigens and kill tumor cells. In our previous studies, we confirmed that the CDR3d region played CDR3d-grafted c9d2T mediate antitumor reactivity H Zhao et al 152 an important role in antigen recognition by the TCRcd. We found that synthesized OEC-derived CDR3d-peptides could mimic the TCRcd and bind specifically to tumor cell lines and tissues 25 A CDR3d-grafted antibody also showed specific binding to several tumor cells 19 We used synthesized OEC-derived CDR3d peptides as probes to search for putative TCR-binding epitopes by screening a 12-mer random peptide phage-displayed library and identified several putative TCR ligands within tumor cell extracts by affinity chromatography and liquid chromatography/electrospray ionization tandem mass spectrometry analysis. Nine peptides and two proteins that bound the cdTCR been identified including human mutS homolog 2, a novel cdTCR ligand 15, 31 Another research group also found that the CDR3d region was responsible for the T22 protein binding specificity of the Vd2 T cells clone G8 32 We had previously constructed full-length PBMCs-derived c9 and d2 chains using overlapping PCR. The fulllength c9 and d2 chains with tumor antigen-specific CDR3 regions were stably transfected into J.RT3-T3.5 by electroporation and expressed functional c9d2TCR 26 In this study, we induced c9 and d2 (OT3) expression in PBLs using a retroviral vector and generated efficient tumor reactive T cells. We chose the retroviral transfection system instead of electroporation to avoid the damage that electroporation causes to primary cells. The resulting CDR3d-grafted c9d2T cells could produce inflammatory cytokines after stimulation with tumor cell extracts and secretion of IFN-c was impaired by treatment with an anti-cdTCR mAb. CDR3d-grafted c9d2T cells were effective at killing tumor cells, and their cytotoxicity was blocked by an anticdTCR mAb. These data demonstrated that the CDR3d-grafted c9d2T cell antitumor response depended on the engineered TCR.
Moreover, in a mouse adoptive transfer model, treatment with CDR3d-grafted c9d2T cells plus IL-2 significantly impaired tumor growth and prolonged the survival of tumor-bearing mice.
Immune effector cells recognize and destroy tumor target cells via two main mechanisms: the death receptor-dependent pathway and the perforin-dependent pathway. The death receptor-dependent pathway acts through interactions between Fas with its ligand FasL. One study investigating the mechanism behind Vc1T-cell cytotoxicity showed that FasL expression and Fas-FasL interactions were necessary for cdT-cell killing of infection-elicited activated macrophages 33 The expression of FasL on effector cells is an inducible process. After antigen recognition, the cytotoxic cells synthesized FasL mRNA de novo, translated it into protein and transported it to the cell surfaces through the Golgi.
Pore-forming proteins are constitutively expressed by peripheral blood cdT cells, 34 suggesting that these proteins play a vital role in cdT-cell cytotoxicity. Moreover, Vc9d2T lymphocytes were reported to kill microorganisms residing in intracellular compartments in a perforin and granzyme-dependant manner. 35 In our study, we used an anti-Fas mAb, BFA and CMA to block CDR3d-grafted c9d2T-cell killing of tumor cells. CMA functions as an inhibitor of the perforin and granzyme pathway by imcreasing the pH of lytic granules to accelerate the degradation of perforin. The anti-Fas mAb blocks the Fas-FasL pathway by blocking ligation of Fas protein expressed on tumor cells. BFA, a protein transport inhibitor, blocks trafficking of FasL to the surface of effector cells. We found that the cytolytic activity of genetically modified c9d2T cells was mediated through both the Fas-dependent and perforindependent pathways, but the perforin-granzyme pathway was dominant. These results demonstrated that cells transfected with the CDR3d-grafted TCR might naturally acquire c9d2TCR-like cytotoxicity towards tumor cells.
Upon activation, cdT cells primarily produce Th1-associated cytokines including IFN-c and TNF-a 36 IFN-c has been described to inhibit tumor proliferation in some models and plays a central role in immune surveillance of tumors. TNF-a has also been reported to play a pivotal role in tumoricidal activity of perforin/IFN-c double knockout effector T cells 37 We found that CDR3d-grafted c9d2T cells secreted IFN-c and TNF-a after antigen stimulation with tumor cell extracts. Moreover, IFN-c secretion was inhibited by treatment of CDR3-grafted c9d2T cell with anti-cdTCR mAbs. These results indicated that genetically modified cdT cells responded directly to tumor antigens and were activated after stimulation with tumor cells.
In conclusion, we have demonstrated that PBLs from healthy donors can be transfected with a c9d2TCR-containing tumor-specific CDR3d regions isolated from OEC TILs. The resulting CDR3d-grafted 
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c9d2T cells secreted high levels of cytokines upon stimulation with tumor cell extracts and exhibited cytotoxicity against tumor cells. Adoptive transfer of CDR3-grafted c9d2T cells slows tumor progression and prolongs the survival of mice inoculated with human tumor cells. These data suggest that CDR3-grafted c9d2T cells are a promising tumor immunotherapy strategy. Further research will focus on optimizing the transfection method and evaluating the mechanism of tumor rejection in greater detail.
